FDA Approves CardioFocus' HeartLight Excalibur Balloon to Treat Paroxysmal Atrial Fibrillation

 

May 7, 2018—CardioFocus, Inc. announced that the US Food and Drug Administration (FDA) has approved the HeartLight Excalibur balloon, the company's next-generation technology designed for the treatment of paroxysmal atrial fibrillation (AF). The company expects to begin a full commercial launch of the Excalibur balloon in the United States in the third quarter of 2018.

According to CardioFocus, the Excalibur combines the balloon design of the company's FDA-approved HeartLight endoscopic ablation system with features that optimize the speed and magnitude of target tissue contact during pulmonary vein isolation procedures.

The Excalibur's ultracompliant design enables adaptive vein conformance. The device incorporates the company's Dynamic Response technology, which allows the user to make real-time adjustments to balloon size for optimal tissue contact. These combined features maximize the engagement of the balloon with the pulmonary veins, while decreasing the time required to complete ablation procedures, stated the company.

The company received CE Mark approval for the device in September 2017 and has launched it in Europe.

In the CardioFocus press release, Vivek Y. Reddy, MD, commented, "We have seen encouraging results with the Excalibur balloon. It obtains an impressive antral position and establishes even more tissue contact, which enables contiguous lesion sets. This is a clear advance in the field of balloon-based AF ablation, delivering on the promise of an ultracompliant balloon." Dr. Reddy is Director of Cardiac Electrophysiology and Helmsley Trust Professor of Medicine at The Icahn School of Medicine at Mount Sinai in New York, New York.

 

Contact Info

For advertising rates and opportunities, contact:
Craig McChesney
484-581-1816
cmcchesney@bmctoday.com

Stephen Hoerst
484-581-1817
shoerst@bmctoday.com

Charles Philip
484-581-1873
cphillip@bmctoday.com

About Cardiac Interventions Today

Cardiac Interventions Today (ISSN 2572-5955 print and ISSN 2572-5963 online) is a publication dedicated to providing comprehensive coverage of the latest developments in technology, techniques, clinical studies, and regulatory and reimbursement issues in the field of coronary and cardiac interventions. Cardiac Interventions Today premiered in March 2007 and each edition contains a variety of topics in a flexible format, including articles covering various perspectives on current clinical topics, in-depth interviews with expert physicians, overviews of available technologies, industry news, and insights into the issues affecting today's interventional cardiology practices.